193 related articles for article (PubMed ID: 18375715)
1. Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease.
Moens AL; Vrints CJ; Claeys MJ; Timmermans JP; Champion HC; Kass DA
Am J Physiol Heart Circ Physiol; 2008 May; 294(5):H1971-7. PubMed ID: 18375715
[TBL] [Abstract][Full Text] [Related]
2. Endothelial dysfunction, endothelial nitric oxide bioavailability, tetrahydrobiopterin, and 5-methyltetrahydrofolate in cardiovascular disease. Where are we with therapy?
Yuyun MF; Ng LL; Ng GA
Microvasc Res; 2018 Sep; 119():7-12. PubMed ID: 29596860
[TBL] [Abstract][Full Text] [Related]
3. Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders.
Gielis JF; Lin JY; Wingler K; Van Schil PE; Schmidt HH; Moens AL
Free Radic Biol Med; 2011 Apr; 50(7):765-76. PubMed ID: 21172428
[TBL] [Abstract][Full Text] [Related]
4. Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy.
Zhang Y; Janssens SP; Wingler K; Schmidt HH; Moens AL
Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H634-46. PubMed ID: 21622818
[TBL] [Abstract][Full Text] [Related]
5. Understanding eNOS for pharmacological modulation of endothelial function: a translational view.
Braam B; Verhaar MC
Curr Pharm Des; 2007; 13(17):1727-40. PubMed ID: 17584103
[TBL] [Abstract][Full Text] [Related]
6. [The pathogenic mechanism of homocysteine -induced endothelial nitric oxide synthase dysfunction and the antagonistic effects by folic acid].
Zhang JG; Wang LZ; Han XQ; Jiang YD; Zhang RM; Wang SR
Fen Zi Xi Bao Sheng Wu Xue Bao; 2007 Feb; 40(1):17-23. PubMed ID: 17357445
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide, caveolae, and vascular pathology.
Li XA; Everson W; Smart EJ
Cardiovasc Toxicol; 2006; 6(1):1-13. PubMed ID: 16845178
[TBL] [Abstract][Full Text] [Related]
8. Novel therapies targeting vascular endothelium.
Tousoulis D; Antoniades C; Koumallos N; Marinou K; Stefanadi E; Latsios G; Stefanadis C
Endothelium; 2006; 13(6):411-21. PubMed ID: 17169773
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease.
Moens AL; Kass DA
J Cardiovasc Pharmacol; 2007 Sep; 50(3):238-46. PubMed ID: 17878750
[TBL] [Abstract][Full Text] [Related]
10. Folic Acid Promotes Recycling of Tetrahydrobiopterin and Protects Against Hypoxia-Induced Pulmonary Hypertension by Recoupling Endothelial Nitric Oxide Synthase.
Chalupsky K; Kračun D; Kanchev I; Bertram K; Görlach A
Antioxid Redox Signal; 2015 Nov; 23(14):1076-91. PubMed ID: 26414244
[TBL] [Abstract][Full Text] [Related]
11. Role of folic acid in nitric oxide bioavailability and vascular endothelial function.
Stanhewicz AE; Kenney WL
Nutr Rev; 2017 Jan; 75(1):61-70. PubMed ID: 27974600
[TBL] [Abstract][Full Text] [Related]
12. Folate, homocysteine, endothelial function and cardiovascular disease.
Moat SJ; Lang D; McDowell IF; Clarke ZL; Madhavan AK; Lewis MJ; Goodfellow J
J Nutr Biochem; 2004 Feb; 15(2):64-79. PubMed ID: 14972346
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol and endothelial nitric oxide.
Xia N; Förstermann U; Li H
Molecules; 2014 Oct; 19(10):16102-21. PubMed ID: 25302702
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
[TBL] [Abstract][Full Text] [Related]
15. The eNOS signalosome and its link to endothelial dysfunction.
Siragusa M; Fleming I
Pflugers Arch; 2016 Jul; 468(7):1125-1137. PubMed ID: 27184745
[TBL] [Abstract][Full Text] [Related]
16. [Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options].
Sydow K; Böger RH
Z Kardiol; 2001 Jan; 90(1):1-11. PubMed ID: 11220081
[TBL] [Abstract][Full Text] [Related]
17. Endothelial nitric oxide synthase enhancer AVE3085 reverses endothelial dysfunction induced by homocysteine in human internal mammary arteries.
Hou HT; Wang J; Zhang X; Wang ZQ; Chen TN; Zhang JL; Yang Q; He GW
Nitric Oxide; 2018 Dec; 81():21-27. PubMed ID: 30300735
[TBL] [Abstract][Full Text] [Related]
18. Endothelium-Derived Nitric Oxide as an Antiatherogenic Mechanism: Implications for Therapy.
Sukhovershin RA; Yepuri G; Ghebremariam YT
Methodist Debakey Cardiovasc J; 2015; 11(3):166-71. PubMed ID: 26634024
[TBL] [Abstract][Full Text] [Related]
19. Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase.
Octavia Y; Kararigas G; de Boer M; Chrifi I; Kietadisorn R; Swinnen M; Duimel H; Verheyen FK; Brandt MM; Fliegner D; Cheng C; Janssens S; Duncker DJ; Moens AL
J Cell Mol Med; 2017 Dec; 21(12):3277-3287. PubMed ID: 28608983
[TBL] [Abstract][Full Text] [Related]
20. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?
Pernow J; Jung C
Cardiovasc Res; 2013 Jun; 98(3):334-43. PubMed ID: 23417041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
